Baidu
map

盘点:7月29日Lancet研究一览

2017-07-28 zhangfan MedSci原创

7月29日Lancet研究一览


【1】封面文章--英国退欧,英国医药的重大损失


英国退欧的阴云弥漫于欧洲大陆。总部位于伦敦的欧洲药品管理局(EMA)将是英国退欧的直接受害者。欧洲药品管理局与欧洲银行管理局(EBA)同为欧盟重要机构,其职责为评估28个成员国的药物使用,为新药在欧盟上市提高统一的评估。自1995年以来,超过1000个品种获EMA批准在欧盟上市。EMA有900名员工,36000名专家评审,每年组织500场相关会议。EMA为英国带来了诸多便利,其提高了英国作为药物发现的科学中心的声誉、增加了英国药物研究能力--从药物安全、流行病学到随机试验和新药评估,加强了英国在药品监管的全球领导作用。若EMA总部离开伦敦将是英国的巨大损失。

【2】托法替尼用于活动期类风湿性关节炎


Roy Fleischmann 等开展了一项名为ORAL Strategy的活动性类风湿关节炎临床研究。参试患者对抗风湿一线药物甲氨蝶呤单独治疗无应答。研究人员比较了不同药物联用甲氨蝶呤对疾病的控制效果后发现,口服JAK抑制剂托法替尼联合甲氨蝶呤可以有效缓解该类患者的疾病症状。

【3】提高直肠癌患者预后及生活质量


大型随机试验的研究结果表明,对于直肠癌患者术前放化疗,相比于单纯手术,局部复发率可降低50%但会导致肛门、直肠和泌尿生殖系统功能障碍。许多临床医生提倡选择性诱导放疗以保持患者的生活质量。Geerard Beets等发现一种治疗效果与生活质量兼顾的方法,即先进行放疗后根据放疗效果确定是否进行手术:对于放疗无应答或较差应答的患者进行直肠系膜全切除手术,对于部分应答患者进行小范围切除手术、对于完全应答患者则无需进行手术。

【4】关注产后抑郁症


毫无疑问,妊娠期和分娩后情绪健康十分重要。情绪发作是常见的产后抑郁症表象,是产妇最常见的精神心理疾病,每10个新生儿母亲中1人受产后抑郁的影响。产后抑郁的严重发作是最严重的精神疾病之一。围产期情绪发作对产妇造成重大损害,对婴儿、家庭和社会产生广泛影响。

【5】关注老年患者抗血小板治疗的胃出血风险


对于缺血性脑卒中,急性冠脉综合征以及有症状的外周动脉疾病患者,抗血小板治疗是是最常见的复发性缺血事件预防方法,最为常用的药物为阿司匹林或氯吡格雷,大多数指南建议终生进行抗血小板治疗。然而,Hans-Christoph Diener等通过随机试验发现抗血小板治疗的获益存在观察期,通常为2-4年之间。研究认为长期的抗血小板治疗的长期利益与风险之间的缺乏研究数据,特别是对于老年患者。

【6】预防阿片药物滥用


2017年5月,美国国会的12名美国国会议员向WHO总干事陈冯富珍写信,信件警告称"鲁莽"、"贪婪"和"危险"美国的阿片类药物制造商Purdue Pharma公司和其全球同行加剧了国际毒品泛滥。Keith Humphreys等议员表示美国正呈现出全国性的阿片类药物使用过量,已经部分导致毒品成瘾,世界各地也应注意阿片药物的滥用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829114, encodeId=bc9818291147f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 01 13:01:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229848, encodeId=959622984844, content=学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Aug 04 07:02:38 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228228, encodeId=8c5522822861, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 31 00:15:51 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227601, encodeId=360222e6014a, content=赞,学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/12/df2ef9fc2a193c8810bc7fe0421e7daf.jpg, createdBy=d2f61706602, createdName=宇文, createdTime=Sat Jul 29 08:46:09 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227203, encodeId=873422e20365, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Jul 28 11:35:15 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2018-03-01 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829114, encodeId=bc9818291147f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 01 13:01:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229848, encodeId=959622984844, content=学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Aug 04 07:02:38 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228228, encodeId=8c5522822861, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 31 00:15:51 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227601, encodeId=360222e6014a, content=赞,学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/12/df2ef9fc2a193c8810bc7fe0421e7daf.jpg, createdBy=d2f61706602, createdName=宇文, createdTime=Sat Jul 29 08:46:09 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227203, encodeId=873422e20365, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Jul 28 11:35:15 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-08-04 hfuym10906

    学习了学习了学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1829114, encodeId=bc9818291147f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 01 13:01:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229848, encodeId=959622984844, content=学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Aug 04 07:02:38 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228228, encodeId=8c5522822861, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 31 00:15:51 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227601, encodeId=360222e6014a, content=赞,学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/12/df2ef9fc2a193c8810bc7fe0421e7daf.jpg, createdBy=d2f61706602, createdName=宇文, createdTime=Sat Jul 29 08:46:09 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227203, encodeId=873422e20365, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Jul 28 11:35:15 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-07-31 luominglian113

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829114, encodeId=bc9818291147f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 01 13:01:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229848, encodeId=959622984844, content=学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Aug 04 07:02:38 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228228, encodeId=8c5522822861, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 31 00:15:51 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227601, encodeId=360222e6014a, content=赞,学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/12/df2ef9fc2a193c8810bc7fe0421e7daf.jpg, createdBy=d2f61706602, createdName=宇文, createdTime=Sat Jul 29 08:46:09 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227203, encodeId=873422e20365, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Jul 28 11:35:15 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-07-29 宇文

    赞,学习!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829114, encodeId=bc9818291147f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 01 13:01:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229848, encodeId=959622984844, content=学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Aug 04 07:02:38 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228228, encodeId=8c5522822861, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 31 00:15:51 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227601, encodeId=360222e6014a, content=赞,学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/12/df2ef9fc2a193c8810bc7fe0421e7daf.jpg, createdBy=d2f61706602, createdName=宇文, createdTime=Sat Jul 29 08:46:09 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227203, encodeId=873422e20365, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Jul 28 11:35:15 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-07-28 189****1577

    值得推荐一下

    0

相关资讯

盘点:7月18日Lancet子刊研究一览

7月18日Lancet子刊研究一览

Lancet Oncol:Gilteritinib可选择性抑制复发或难治性AML的FLT3突变

约三成的复发或难治性AML患者会出现FLT3突变。体外试验显示,gilteritinib可对FLT3选择性抑制,但是还没有人体试验数据。6月20日在线发表于Lancet Oncology上的一篇文章表示,FLT3突变的复发或难治性AML患者中,gilteritinib的安全性特征良好,应答持续时间长,总体生存结局令人鼓舞。

盘点:Lancet杂志7月15日文章一览

Lancet杂志7月15日文章一览

盘点:2017年7月15日Lancet研究一览

2017年7月15日Lancet研究一览

盘点:2017年7月14日Lancet研究一览

2017年7月14日Lancet杂质研究一览

盘点:Lancet杂志7月22日研究一览

Lancet杂志7月22日研究一览

Baidu
map
Baidu
map
Baidu
map